Favipiravir ameliorates bleomycin-induced pulmonary fibrosis by reprogramming M1/M2 macrophage polarization
Ruiqin Zhang, Qiuyan Jiang, Shaoyan Gao, Huizhe Zhang, Qin Xia, Bowen Liu, Jingyan Zhu, Haixia Jiang, Ruixi Zhao, Huixuan Dong, Xiaohe Li, Yanping Zhang, Cheng Yang, Xiaoting Gu, Liang Sun, Honggang Zhou
Topics & Concepts
Pulmonary fibrosisBleomycinFibrosisMacrophage polarizationMedicineInflammationImmunologyIdiopathic pulmonary fibrosisFavipiravirPopulationMacrophageImmune systemLungPathologyBiologyDiseaseInternal medicineChemotherapyInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)In vitroBiochemistryEnvironmental healthInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhagocytosis and Immune RegulationExtracellular vesicles in disease